TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02767921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Undergo robotic-assisted radical cystectomy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo robotic-assisted radical or partial nephrectomy
Study: NCT01278095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0555 solid dispersion
Description: solid dispersion capsules, 50 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0555 solid dispersion
Description: solid dispersion capsules, 50 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0555 nanosuspension
Description: Nanosuspension, 50 mg, single dose
Study: NCT02100761

Intervention type: DRUG
Intervention: Voriconazole
Description: Patients with creatinine clearance at least 50 ml/min will be treated with voriconazole by intravenous drip infusion at the dose of 6 mg/kg twice daily on the first day (Day 1) and 4 mg/kg twice daily from day 2 onward. The IV treatment is at least 7 days. Then switch to 200 mg orally twice daily between meals. The total treatment duration is at least 14 days Patients with creatinine clearance \<50 ml/min will be treated with oral voriconazole (loading dose of 400 mg twice daily followed by maintenance dose of 200 mg twice daily between meals for at least 14.0 days).
Study: NCT03549793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Therapy
Description: the intervention is aimed to ameliorate, through dancing, crucial motor symptoms in PD patients, as walking, balance, postural changes and arm swing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercises without dance
Description: the intervention consists of exercises aimed at training the walking, the balance, the postural changes and the arm swing
Study: NCT01464905

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NU100
Description: 0.25 mg SQ, every other day for 12 months

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL SQ, every other day for 4 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rhIFN beta-1b
Description: 0.25 mg SQ, every other day for 12 months
Study: NCT00871507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38431055 Dose 1
Description: Liquid suspension/solution of JNJ-38431055 administered as a single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100 mg
Description: Capsule containing 100 mg of sitagliptin administered as a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo suspension/solution and Placebo capsule administered as single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38431055 Dose 2
Description: Liquid suspension/solution of JNJ-38431055 administered as a single dose
Study: NCT00627952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine 10 mg
Description: amlodipine 10 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: manidipine 20 mg
Description: manidipine 20 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine 5 mg + delapril 30 mg
Description: amlodipine 5 mg + delapril 30 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: manidipine 10 mg + delapril 30 mg
Description: manidipine 10 mg + delapril 30 mg once daily
Study: NCT02417493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation of epinephrine self-injection
Study: NCT01006603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5 mg, oral tablet, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1, 2, 3, 4 or 6 mg, oral encapsulated tablet, once daily
Study: NCT03703401

Intervention type: DIAGNOSTIC_TEST
Intervention: Hysterosalpingo-contrast-sonogram
Description: A contrast ultrasound scan to examine fallopian tube pathology and blockage

Intervention type: DIAGNOSTIC_TEST
Intervention: Hysterosalpingo-contrast-sonogram
Description: A contrast ultrasound scan to examine fallopian tube pathology and blockage

Intervention type: DIAGNOSTIC_TEST
Intervention: Hysterosalpingo-contrast-sonogram
Description: A contrast ultrasound scan to examine fallopian tube pathology and blockage
Study: NCT00613067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: * Start with escitalopram 10mg~* According to patient's symptoms, stay on 10mg or increase up to 20mg~* Concomitant therapy : up to Xanax 0.5mg, or Ativan 1mg, not allowed above these dosages~* Length of washout period will be at least 2 weeks for any psychotropic drugs
Study: NCT02814500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R212
Description: Investigational product is prescribed to all of randomized subjects
Study: NCT04395222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen
Study: NCT01955616

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04395222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen.
Study: NCT00936520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR 1118 0.1%
Description: Daily eye drops (twice daily, \~50 microliter \[uL\] each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR 1118 1.0%
Description: Daily eye drops (twice daily, \~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
Study: NCT05461443

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Study: NCT02814500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R212
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Investigational product is prescribed to all of randomized subjects
Study: NCT00936520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR 1118 5.0%
Description: Daily eye drops (twice daily, \~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
Study: NCT03652194

Intervention type: OTHER
Intervention: in vitro evaluation of epithelial immune response during C. glabrata infection
Description: 1. study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade~2. study of protein expression by the Western-Blot method

Intervention type: OTHER
Intervention: in vitro evaluation of epithelial immune response during C. glabrata infection
Description: 1. study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade~2. study of protein expression by the Western-Blot method

Intervention type: OTHER
Intervention: in vitro evaluation of epithelial immune response during C. glabrata infection
Description: 1. study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade~2. study of protein expression by the Western-Blot method

Intervention type: OTHER
Intervention: study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates
Description: 1. in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.~2. in vivo evaluation measured by a survival study on a CD-1 mouse model.

Intervention type: OTHER
Intervention: study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates
Description: 1. in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.~2. in vivo evaluation measured by a survival study on a CD-1 mouse model.

Intervention type: OTHER
Intervention: study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates
Description: 1. in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.~2. in vivo evaluation measured by a survival study on a CD-1 mouse model.
Study: NCT01224808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostate
Description: Single bolus doses, administered intravenously. Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
Study: NCT04395222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen.
Study: NCT02814500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Investigational product is prescribed to all of randomized subjects
Study: NCT01156064

Intervention type: DEVICE
Intervention: Confocal Laser Endomicroscopy (Pentax/Optiscan)
Description: Confocal laser endomicroscopy is performed using the Pentax/Optiscan confocal endomicroscopy and 5 ml of 10% intravenous fluorescein sodium. Photos of magnified images of the digestive mucosa are taken during the procedure.

Intervention type: DEVICE
Intervention: Confocal Laser Endomicroscopy (Pentax/Optiscan)
Description: Confocal laser endomicroscopy is performed using the Pentax/Optiscan confocal endomicroscopy and 5 ml of 10% intravenous fluorescein sodium. Photos of magnified images of the digestive mucosa are taken during the procedure.

Intervention type: DEVICE
Intervention: Narrow Band Imaging/Auto Fluorescence Imaging (Olympus)
Description: NBI/AFI endoscope offers an alternative light source involve NBI and AFI to view digestive mucosa in real time.

Intervention type: DEVICE
Intervention: Narrow Band Imaging/Auto Fluorescence Imaging (Olympus)
Description: NBI/AFI endoscope offers an alternative light source involve NBI and AFI to view digestive mucosa in real time.
Study: NCT01180179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: 30mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: 40mg once daily
Study: NCT00813540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: The exercise group will perform supervised stationary cycle ergometer exercise 3 times per week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 110% of the power output obtained at V02peak. Resistance training will be completed twice per week and will include exercises for all major muscle groups. The training will progress from 60% to 80% of 1RM over the course of the intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual Care
Study: NCT02438358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LUM 2.6 Imaging Device
Study: NCT01335802

Intervention type: GENETIC
Description: Genetic counseling
Study: NCT04555915

Intervention type: OTHER
Intervention: Monitoring of cerebral oxygenation
Description: Modify cardio-respiratory support to avoid cerebral hypoxia
Study: NCT05490992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Skills Training In-person
Description: Both an in-person and virtual telehealth version of Behavioral Skills Training (BST) was compared to the Car seat check-up traditional car seat educational method and BST telehealth was compared to BST in-person.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Skills Training In-person
Description: Both an in-person and virtual telehealth version of Behavioral Skills Training (BST) was compared to the Car seat check-up traditional car seat educational method and BST telehealth was compared to BST in-person.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Skills Training In-person
Description: Both an in-person and virtual telehealth version of Behavioral Skills Training (BST) was compared to the Car seat check-up traditional car seat educational method and BST telehealth was compared to BST in-person.
Study: NCT04187027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed electromagnetic field therapy device
Description: magnetic field stimulation (MFS) is a novel technique for stimulating the nervous system non-invasively, which can activate deep neural structures via induced electric currents, without pain and discomfort. Also, several clinical trials including placebo-controlled studies have shown that MFS of the pelvic floor and sacral roots is effective for overactive bladder (OAB). MFS induces inhibitory effects on detrusor overactivity in a similar manner to electrical stimulation, with significant clinical advantages. MFS of the sacral nerve roots could be a promising alternative treatment for OAB.
Study: NCT03282032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One-lung ventilation
Description: The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, 5 cycles of one-lung ventilation preconditioning (2-min of one-lung ventilation and 2-min of two-lung ventilation for 1 cycle) is performed before surgical incision. One-lung ventilation is done at dependent lung with FiO2 100% and tidal volume 6 ml kg-1. Two-lung ventilation is done with FiO2 50%, tidal volume 8 ml kg-1.
Study: NCT01901887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Juice
Description: The intervention will be 3 boxes/day for 6 months of SMARTFISH® Nutrifriend 1100, a commercially available smoothie juice box containing 1,100 mg of omega-3 HUFAs/200 ml box (approximately 550 mg EPA and 550 mg DHA/box) for a total of 3,300 mg of omega-3 HUFAs/day (approximately 1,650 mg EPA and 1,650 mg DHA/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Juice
Description: The placebo will be 3 boxes/day for 6 months of a placebo juice which will be identical to the study juice except that it will substitute 1,100 mg of macadamia nut oil/200 ml juice box in place of the omega-3 HUFAs for a total of 3,300 mg of macadamia nut oil/day.
Study: NCT03885921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: oral tablet
Study: NCT00371319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: 0.06-0.1 mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: 2-3 gm/day
Study: NCT04395222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (rabbit)
Description: Anti-thymocyte globulin (ATG) 1.5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (rabbit)
Description: Anti-thymocyte globulin (ATG) 1.5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (rabbit)
Description: Anti-thymocyte globulin (ATG) 1.5 mg/kg
Study: NCT04395222

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen
Study: NCT03483922

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA methylation in and it's Correlation wth Development and prediction of HCC
Description: Blood sample from patients with HCC, healthy individuals and individuals with hepatitis B will be collected, and DNA will extracted from PBMC and circulated tumor DNA will be subjected to bisulfite conversion. DNA from PBMC DNA will be analyzed with primers developed for the AHNAK-STAP1 genes. Plasma samples will be subjected to EZ direct DNA extraction and bisulfite conversion kit and will be amplified with primers developed to amplify the target regions. DNA will be used for the subsequent PCR amplification with specific primer to generate PCR amplicon for sequencing using a double PCR procedure. The product of PCR reaction will be subjected to indexed MiSeq Next-Generation sequencing that will allow us quantify DNA methylation level.

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA methylation in and it's Correlation wth Development and prediction of HCC
Description: Blood sample from patients with HCC, healthy individuals and individuals with hepatitis B will be collected, and DNA will extracted from PBMC and circulated tumor DNA will be subjected to bisulfite conversion. DNA from PBMC DNA will be analyzed with primers developed for the AHNAK-STAP1 genes. Plasma samples will be subjected to EZ direct DNA extraction and bisulfite conversion kit and will be amplified with primers developed to amplify the target regions. DNA will be used for the subsequent PCR amplification with specific primer to generate PCR amplicon for sequencing using a double PCR procedure. The product of PCR reaction will be subjected to indexed MiSeq Next-Generation sequencing that will allow us quantify DNA methylation level.

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA methylation in and it's Correlation wth Development and prediction of HCC
Description: Blood sample from patients with HCC, healthy individuals and individuals with hepatitis B will be collected, and DNA will extracted from PBMC and circulated tumor DNA will be subjected to bisulfite conversion. DNA from PBMC DNA will be analyzed with primers developed for the AHNAK-STAP1 genes. Plasma samples will be subjected to EZ direct DNA extraction and bisulfite conversion kit and will be amplified with primers developed to amplify the target regions. DNA will be used for the subsequent PCR amplification with specific primer to generate PCR amplicon for sequencing using a double PCR procedure. The product of PCR reaction will be subjected to indexed MiSeq Next-Generation sequencing that will allow us quantify DNA methylation level.
Study: NCT00008450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic bone marrow transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT05259241

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: activated partial thrombin time
Description: This study aims to find which the point-of-care test (ACT or APTT) has the best correlation with the coagulation status during transcatheter cardiac interventions (either TAVR or PCI)
Study: NCT03453476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SRP and Fotosan 630
Description: After isolating the test quadrants with cotton roll, toluidine blue was applied into the deep pockets (PD ≥ 4mm) at the test quadrants for 10 seconds, followed by inserting a perio tip (15 or 21 mm depending on the depth of the pocket) that connected to a LED emitting device, and light was emitted for 20 seconds. Toluidine blue in the deep pocket was removed by injecting normal saline into the pocket.